반응식
[C:1]([O:5][C:6]([N:8]1[CH2:13][CH2:12][CH:11]([O:14][C:15]2[CH:24]=[C:23]([O:25][CH3:26])[CH:22]=[C:21]3[C:16]=2[C:17]([Cl:27])=[N:18][CH:19]=[N:20]3)[CH2:10][CH2:9]1)=[O:7])([CH3:4])([CH3:3])[CH3:2].[Cl:28][C:29]1[C:34]([NH2:35])=[C:33]2[O:36][CH2:37][O:38][C:32]2=[CH:31][CH:30]=1>>[ClH:27].[ClH:28].[C:1]([O:5][C:6]([N:8]1[CH2:9][CH2:10][CH:11]([O:14][C:15]2[CH:24]=[C:23]([O:25][CH3:26])[CH:22]=[C:21]3[C:16]=2[C:17]([NH:35][C:34]2[C:29]([Cl:28])=[CH:30][CH:31]=[C:32]4[O:38][CH2:37][O:36][C:33]=24)=[N:18][CH:19]=[N:20]3)[CH2:12][CH2:13]1)=[O:7])([CH3:4])([CH3:3])[CH3:2]참가 물질
3
실험 절차
Using an analogous procedure to that also described in the portion of Example 31 that is concerned with the preparation of starting materials, 5-(1-tert-butoxycarbonylpiperidin-4-yloxy)-4-chloro-7-methoxyquinazoline (0.14 g) and 6-chloro-2,3-methylenedioxyaniline (0.064 g) were reacted to give 5-(1-tert-butoxycarbonylpiperidin-4-yloxy)-4-(6-chloro-2,3-methylenedioxyanilino)-7-methoxyquinazoline dihydrochloride (0.17 g); NMR Spectrum: (DMSOd6) 1.42 (s, 9H), 1.8-2.0 (m, 2H), 2.0-2.15 (m, 2H), 3.0-3.2 (m, 2H), 3.85-3.95 (m, 2H), 3.99 (s, 3H), 5.1 (m, 1H), 6.96 (d, 1H), 7.05 (d, 1H), 7.12 (s, 1H), 7.15 (d, 1H), 8.78 (s, 1H), 10.1 (s, 1H); Mass Spectrum: M+H+ 529 and 531.
후처리
- customwere reacted
출처 및 근거
- ORD 기록
- ord-bbb8eb7667734d92a9c4464aca3525d6
- 출처 데이터셋
- uspto-grants-2010_04
- 특허 번호
- US07696214B2
연결된 노트
불러오는 중…